search
Back to results

Bringing Relief to Adolescents Naturally Using Melatonin for Migraine (BRAiN-M)

Primary Purpose

Migraine in Adolescents

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Melatonin
Placebo
Sponsored by
Amy Gelfand
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Migraine in Adolescents

Eligibility Criteria

12 Years - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age 12-17 years and weight ≥40 kg, to allow consistent dosing for all participants of the melatonin dose that has been found to be effective in adults
  2. Resides in California
  3. Headache fulfills International Classification for Headache Disorders, Third Edition (beta version)33 criteria for episodic migraine (with or without aura) in adolescents
  4. Has been experiencing episodic headaches for at least six months
  5. Experiences between 6-14 days of migraine/migrainous headaches per month at baseline (cutoff for chronic migraine is ≥15 days/month)
  6. Developmentally able to provide age-appropriate level of assent
  7. Has a parent/guardian capable of giving written informed consent
  8. Has daily access to a smartphone in order to be able to complete daily study procedures such as diary completion, and to receive text reminders
  9. Subject and parent agree the adolescent will not use over-the-counter melatonin, or another migraine preventive medication, while participating in the study
  10. Participant and at least one parent speak English

Exclusion Criteria:

  1. Currently (or within the last 4 weeks) using any medication or device with migraine preventive properties: i.e. topiramate, amitriptyline, nortriptyline, propranolol, metoprolol, sodium valproate, gabapentin, flunarizine, methysergide, riboflavin, butterbur, coenzyme Q10, or the Cefaly TENS device. For onabotulinum toxin, they will have to have been off it for at least three months
  2. Use of other sleep medication or sedating medication, such as benzodiazepines, trazodone, or melatonin receptor agonists
  3. History of allergy or adverse event with previous use of exogenous melatonin
  4. Previous ineffective trial of melatonin 3 mg nightly for migraine prevention, where the trial duration was at least three months in duration
  5. Inability to swallow pills, if this inability persists after instruction on pill-swallowing techniques
  6. History of epilepsy or seizure
  7. Overuse of acute headache medications, wherein medication overuse is defined33 as ≥4 days per month of barbiturate containing compounds, ≥10 days per month of opioid containing compounds, or ≥10 days per month of triptans or ergot-containing compounds. Those using non-specific analgesics ≥15 days per month would also be excluded
  8. Adolescent does not have the cognitive capacity to give verbal assent to participate, or the investigator thinks the adolescent does not have the cognitive capacity to complete the diary, even with parental assistance
  9. For females: Pregnancy, lactating or planning to become pregnant during the study. For males: planning to father a child during the study
  10. Abnormal neurologic examination findings
  11. Serious medical illness of any kind; seriousness as judged by the investigator
  12. The investigator does not think the participant can comply with study procedures, or does not think it is medically appropriate for the participant to be in the study

Sites / Locations

  • UCLA Headache Research and Treatment Program
  • UCSF Pediatric Brain Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Melatonin

Placebo

Arm Description

Group randomized to melatonin 3 mg orally nightly

Group randomized to placebo orally nightly

Outcomes

Primary Outcome Measures

Number of Migraine/Migrainous Days Per 28 Day Period
Number of Migraine/Migrainous Days Per 28 Day Period in melatonin group and placebo group as measured using an online/mobile device headache diary.

Secondary Outcome Measures

Number of Minutes to Sleep Onset
Number of minutes to sleep onset as measured by a FitBit.
Number of Participants Recruited From Each Recruitment Strategy
Each recruitment strategy will be analyzed for number of participants successfully enrolled.
Medication Adherence as Measured by Number of Openings Per Participant
eCAP tack caps will be used to measure medication adherence and the number of openings will be recorded per participant.
Headache Diary Compliance Rate
Number of participants that had ≥85% headache diary compliance during weeks 12-16 of the study.

Full Information

First Posted
January 12, 2015
Last Updated
August 13, 2021
Sponsor
Amy Gelfand
Collaborators
University of California, Los Angeles
search

1. Study Identification

Unique Protocol Identification Number
NCT02344316
Brief Title
Bringing Relief to Adolescents Naturally Using Melatonin for Migraine
Acronym
BRAiN-M
Official Title
Melatonin for Migraine Prevention in Adolescents: A Pilot Remote Trial: "The BRAiN-M Study"
Study Type
Interventional

2. Study Status

Record Verification Date
August 2021
Overall Recruitment Status
Completed
Study Start Date
May 2015 (undefined)
Primary Completion Date
April 2016 (Actual)
Study Completion Date
April 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Amy Gelfand
Collaborators
University of California, Los Angeles

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Migraine in adolescents is common and effective and safe preventive treatments are needed. This is a pilot randomized controlled trial of melatonin versus placebo for migraine prevention in adolescents 12-17 years old.
Detailed Description
This is a pilot randomized controlled trial of melatonin vs. placebo for migraine prevention in adolescents 12-17 years old. The main goal of this pilot study is to estimate variance in the outcome measures to help with planning the future fully powered study. Participants will have an in person enrollment visit, followed by phone follow up visits and headache diary data collection via smart phone or internet.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Migraine in Adolescents

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
31 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Melatonin
Arm Type
Active Comparator
Arm Description
Group randomized to melatonin 3 mg orally nightly
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Group randomized to placebo orally nightly
Intervention Type
Drug
Intervention Name(s)
Melatonin
Other Intervention Name(s)
Rugby melatonin
Intervention Description
Taken at 9 PM or 1 hour before bedtime, whichever is earlier
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Matching placebo taken at 9 PM or 1 hour before bedtime, whichever is earlier
Primary Outcome Measure Information:
Title
Number of Migraine/Migrainous Days Per 28 Day Period
Description
Number of Migraine/Migrainous Days Per 28 Day Period in melatonin group and placebo group as measured using an online/mobile device headache diary.
Time Frame
final 4 weeks of treatment
Secondary Outcome Measure Information:
Title
Number of Minutes to Sleep Onset
Description
Number of minutes to sleep onset as measured by a FitBit.
Time Frame
16 weeks
Title
Number of Participants Recruited From Each Recruitment Strategy
Description
Each recruitment strategy will be analyzed for number of participants successfully enrolled.
Time Frame
During the enrollment period, approximately 1 year
Title
Medication Adherence as Measured by Number of Openings Per Participant
Description
eCAP tack caps will be used to measure medication adherence and the number of openings will be recorded per participant.
Time Frame
during the "At Home Active Study Period" or Weeks 5-16
Title
Headache Diary Compliance Rate
Description
Number of participants that had ≥85% headache diary compliance during weeks 12-16 of the study.
Time Frame
Weeks 12-16 of the study

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 12-17 years and weight ≥40 kg, to allow consistent dosing for all participants of the melatonin dose that has been found to be effective in adults Resides in California Headache fulfills International Classification for Headache Disorders, Third Edition (beta version)33 criteria for episodic migraine (with or without aura) in adolescents Has been experiencing episodic headaches for at least six months Experiences between 6-14 days of migraine/migrainous headaches per month at baseline (cutoff for chronic migraine is ≥15 days/month) Developmentally able to provide age-appropriate level of assent Has a parent/guardian capable of giving written informed consent Has daily access to a smartphone in order to be able to complete daily study procedures such as diary completion, and to receive text reminders Subject and parent agree the adolescent will not use over-the-counter melatonin, or another migraine preventive medication, while participating in the study Participant and at least one parent speak English Exclusion Criteria: Currently (or within the last 4 weeks) using any medication or device with migraine preventive properties: i.e. topiramate, amitriptyline, nortriptyline, propranolol, metoprolol, sodium valproate, gabapentin, flunarizine, methysergide, riboflavin, butterbur, coenzyme Q10, or the Cefaly TENS device. For onabotulinum toxin, they will have to have been off it for at least three months Use of other sleep medication or sedating medication, such as benzodiazepines, trazodone, or melatonin receptor agonists History of allergy or adverse event with previous use of exogenous melatonin Previous ineffective trial of melatonin 3 mg nightly for migraine prevention, where the trial duration was at least three months in duration Inability to swallow pills, if this inability persists after instruction on pill-swallowing techniques History of epilepsy or seizure Overuse of acute headache medications, wherein medication overuse is defined33 as ≥4 days per month of barbiturate containing compounds, ≥10 days per month of opioid containing compounds, or ≥10 days per month of triptans or ergot-containing compounds. Those using non-specific analgesics ≥15 days per month would also be excluded Adolescent does not have the cognitive capacity to give verbal assent to participate, or the investigator thinks the adolescent does not have the cognitive capacity to complete the diary, even with parental assistance For females: Pregnancy, lactating or planning to become pregnant during the study. For males: planning to father a child during the study Abnormal neurologic examination findings Serious medical illness of any kind; seriousness as judged by the investigator The investigator does not think the participant can comply with study procedures, or does not think it is medically appropriate for the participant to be in the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Amy A Gelfand, MD
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
Facility Information:
Facility Name
UCLA Headache Research and Treatment Program
City
Los Angeles
State/Province
California
ZIP/Postal Code
90077
Country
United States
Facility Name
UCSF Pediatric Brain Center
City
San Francisco
State/Province
California
ZIP/Postal Code
94158
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
19817880
Citation
Masruha MR, Lin J, de Souza Vieira DS, Minett TS, Cipolla-Neto J, Zukerman E, Vilanova LC, Peres MF. Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities. Headache. 2010 Mar;50(3):413-9. doi: 10.1111/j.1526-4610.2009.01547.x. Epub 2009 Oct 8.
Results Reference
background
PubMed Identifier
18594760
Citation
Masruha MR, de Souza Vieira DS, Minett TS, Cipolla-Neto J, Zukerman E, Vilanova LC, Peres MF. Low urinary 6-sulphatoxymelatonin concentrations in acute migraine. J Headache Pain. 2008 Aug;9(4):221-4. doi: 10.1007/s10194-008-0047-5. Epub 2008 Jul 2.
Results Reference
background
PubMed Identifier
16548786
Citation
Peres MF, Masruha MR, Zukerman E, Moreira-Filho CA, Cavalheiro EA. Potential therapeutic use of melatonin in migraine and other headache disorders. Expert Opin Investig Drugs. 2006 Apr;15(4):367-75. doi: 10.1517/13543784.15.4.367.
Results Reference
background
PubMed Identifier
15326268
Citation
Peres MF, Zukerman E, da Cunha Tanuri F, Moreira FR, Cipolla-Neto J. Melatonin, 3 mg, is effective for migraine prevention. Neurology. 2004 Aug 24;63(4):757. doi: 10.1212/01.wnl.0000134653.35587.24. No abstract available.
Results Reference
background
PubMed Identifier
11723194
Citation
Peres MF, Sanchez del Rio M, Seabra ML, Tufik S, Abucham J, Cipolla-Neto J, Silberstein SD, Zukerman E. Hypothalamic involvement in chronic migraine. J Neurol Neurosurg Psychiatry. 2001 Dec;71(6):747-51. doi: 10.1136/jnnp.71.6.747.
Results Reference
background
PubMed Identifier
24909684
Citation
Fallah R, Shoroki FF, Ferdosian F. Safety and efficacy of melatonin in pediatric migraine prophylaxis. Curr Drug Saf. 2015;10(2):132-5. doi: 10.2174/1574886309666140605114614.
Results Reference
background

Learn more about this trial

Bringing Relief to Adolescents Naturally Using Melatonin for Migraine

We'll reach out to this number within 24 hrs